Empagliflozin as Add-on Therapy to Pioglitazone with or Without Metformin in Patients with Type 2 Diabetes Mellitus

Clinical Therapeutics

Volumn 37, Issue 8, 2015, Pages 1773-1788.e1

  Kovacs, Christopher S ^a   Seshiah, Veeraswamy ^b   Merker, Ludwig ^c   Christiansen, Anita Vedel ^d   Roux, Flavien ^e   Salsali, Afshin ^d   Kim, Gabriel ^d   Stella, Peter ^d   Woerle, Hans Juergen ^d   Broedl, Uli C ^d  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Diabetes Research Institute   (India)

^c Diabetes und Nierenzentrum   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e BOEHRINGER INGELHEIM   (France)

Author keywords

glycemic control; Key words empagliflozin; metformin; pioglitazone; SGLT2; type 2 diabetes mellitus

Indexed keywords

CALCIUM; CHOLESTEROL; CREATININE; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; METFORMIN; PHOSPHATE; PIOGLITAZONE; PLACEBO; POTASSIUM; SODIUM; TRIACYLGLYCEROL; URIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN;

ADD ON THERAPY; ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BODY WEIGHT; CALCIUM BLOOD LEVEL; CHEMOTHERAPY INDUCED ANEMIA; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; EXPLORATORY RESEARCH; FEMALE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGLYCEMIA; LONG TERM CARE; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; RHINOPHARYNGITIS; SENSITIVITY ANALYSIS; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; AGED; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84940575211     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.05.511     Document Type: Article

References (22)

1. R.A. DeFronzo Banting Lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 2009 773 795
2. R.C. Turner, C.A. Cull, V. Frighi, and R.R. Holman Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA 281 1999 2005 2012
3. J.B. Brown, C. Conner, and G.A. Nichols Secondary failure of metformin monotherapy in clinical practice Diabetes Care 33 2010 501 506
4. R.A. DeFronzo, J.A. Davidson, and S. del Prato The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia Diabetes Obes Metab 14 2012 5 14
5. R. Grempler, L. Thomas, M. Eckhardt, and et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors Diabetes Obes Metab 14 2012 83 90
6. T. Heise, E. Seewaldt-Becker, S. Macha, and et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes Diabetes Obes Metab 15 2013 613 621
7. C.S. Kovacs, V. Seshiah, R. Swallow, and et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial Diabetes Obes Metab 16 2013 147 158
8. M. Roden, J. Weng, J. Eilbracht, and et al. Empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a randomised, 24-week, double-blind, placebo-controlled, parallel group, trial with sitagliptin as active comparator Lancet Diabetes Endocrinol 1 2013 208 219
9. H.-U. Haering, L. Merker, E. Seewaldt-Becker, and et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial Diabetes Care 37 2014 1650 1659
10. A.H. Barnett, A. Mithal, J. Manassie, and et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol 2 2014 369 384
11. M. Ridderstrale, K.R. Andersen, C. Zeller, and et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial Lancet Diabetes Endocrinol 2 2014 691-670
12. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420-428.
13. Takeda Pharmaceuticals America, Inc. Actos (pioglitazone) Prescribing Information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/021073s046lbl.pdf Accessed October 30, 2014.
14. J.A. Dormandy, B. Charbonnel, D.J. Eckland, and et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
15. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, and et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
16. S. Klein, N.F. Sheard, X. Pi-Sunyer, and et al. Weight modification through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition Diabetes Care 27 2004 2067 2073
17. J. Ybarra, R.W. James, V. Makoundou, and et al. Effects of short-term modest weight loss on fasting and post-prandial lipoprotein sub-fractions in type 2 diabetes mellitus patients Diabetes Metab 27 2001 701 708
18. D.F. Williamson, T.J. Thompson, M. Thun, and et al. Intentional weight loss and mortality among overweight individuals with diabetes Diabetes Care 23 2000 1499 1504
19. O.J. Phung, J.M. Scholle, M. Talwar, and C.I. Coleman Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes JAMA 303 2010 1410 1418
20. L. Blonde, E.J. Klein, J. Han, and et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes Diabetes Obes Metab 8 2006 436 447
21. K. Stenlöf, W.T. Cefalu, K.A. Kim, and et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study Curr Med Res Opin 30 2014 163 175
22. D. Williams-Herman, J. Johnson, R. Teng, and et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes Diabetes Obes Metab 12 2010 442 451